Acil Serviste Konjestif Kalp Yetmezliği Yönetiminde Loop Diüretiklerinin Rolü: Bumetanid ve Furosemid Kıyaslaması

Hidayet Tuğba ÇİÇEK; Mahmut Köylü; Buket Tosun

doi:10.5281/zenodo.17251560

Authors

Hidayet Tuğba ÇİÇEK Trabzon Kanuni EAH
Mahmut Köylü Çukurova University https://orcid.org/0009-0004-2106-983X
Buket Tosun Kanuni Eğitim ve Araştırma Hastanesi https://orcid.org/0000-0002-5021-7414

DOI:

https://doi.org/10.5281/zenodo.17251560

Keywords:

Heart Failure, Bumetanide, Diuretic

Abstract

Objective: To comparatively evaluate the effect profiles, pharmacological properties and clinical efficacy of bumetanide and furosemide, which are loop diuretics frequently used in patients presenting to the emergency department with the diagnosis of heart failure. Heart failure is a serious condition that threatens public health due to its high morbidity and mortality rates. The definition, classification and understanding of risk factors of the disease are of great importance for effective treatment planning.

Material and Methods: Within the scope of this study, national and international literature was reviewed and the pharmacological properties, clinical areas of use and effects of bumetanide and furosemide in the emergency department were examined. Comparative studies focusing on the use of the two agents in emergency department conditions were evaluated.

Findings: It shows that bumetanide has a more predictable pharmacokinetic profile compared to furosemide, but provides similar results in terms of clinical efficacy.

Discussion and Conclusion: The correct choice of diuretic in the emergency department is vital for rapid relief of symptoms and prognosis. However, evidence on this subject is limited. Therefore, the review aims to bring together the available scientific data to enable rational selection among diuretics used in the emergency department.

References

Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37(27):2129-200. doi:10.1093/eurheartj/ehw128.

Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure. J Am Coll Cardiol. 2017;70(6):776-803. doi:10.1016/j.jacc.2017.04.025.

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-726. doi:10.1093/eurheartj/ehab368.

Grahnén A, Hammarlund M, Lundqvist T. Intraindividual variability in bioavailability studies of furosemide. Eur J Clin Pharmacol. 1984;27(5):595-602. doi:10.1007/BF00556898.

Brater DC. Disposition and response to bumetanide and furosemide. Am J Cardiol. 1986;57(2):20A-5A. doi:10.1016/0002-9149(86)91002-7.

Mueller C, McDonald K, de Boer RA, Maisel A, Cleland JGF, Kozhuharov N, et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail. 2019;21(6):715-31. doi:10.1002/ejhf.1494.

Felker GM, Mentz RJ. Diuretics and ultrafiltration in acute decompensated heart failure. J Am Coll Cardiol. 2012;59(24):2145-53. doi:10.1016/j.jacc.2011.09.088.

Casu G, Merella P. Diuretic therapy in heart failure – current approaches. Eur Cardiol Rev. 2015;10(1):42-7. doi:10.15420/ecr.2015.10.01.42.

Ramsay LE, McInnes GT, Hettiarachchi J, Shelton J, Scott P. Bumetanide and frusemide: a comparison of dose-response curves in healthy men. Br J Clin Pharmacol. 1978;5(3):243-7. doi:10.1111/j.1365-2125.1978.tb01631.x.

Sağkan O, Aykın A. Bumetanid: yeni bir loop diüretiği. J Exp Clin Med. 2009;8(2). doi:10.5835/jecm.v8i2.1180.

Brater DC, Chennavasin P, Day B, Burdette A, Anderson S. Bumetanide and furosemide. Clin Pharmacol Ther. 1983;34(2):207-13. doi:10.1038/clpt.1983.154.

Eid PS, Ibrahim DA, Zayan AH, Elrahman MMA, Shehata MAA, Kandil H, et al. Comparative effects of furosemide and other diuretics in the treatment of heart failure: a systematic review and combined meta-analysis of randomized controlled trials. Heart Fail Rev. 2021; 26(1):127–36. doi:10.1007/s10741-020-10003-7

Nappi JM. A retrospective evaluation of the efficacy of intravenous bumetanide and comparison of potency with furosemide. Pharm Pract (Granada). 2013;11(1):44-50. doi:10.4321/s1886-36552013000100008.

Wilson BJ, Bates D. Diuretic Strategies in Acute Decompensated Heart Failure: A Narrative Review. Can J Hosp Pharm. 2024;77(1):e3323. doi: 10.4212/cjhp.3323.

Ellison DH, Felker GM. Diuretic treatment in heart failure. N Engl J Med. 2017;377(20):1964–75. doi: 10.1056/NEJMra1703100.

Pan A, Stiell IG, Dionne R & Maloney J. Prehospital use of furosemide for the treatment of heart failure. Emergency Medicine Journal, 2014; 32(1): 36 - 43. doi: 10.1136/emermed-2013-202874.